Evidence map›Paper›PMID 38030264›Full record

SynthesisBMJ open respiratory research2023

Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis.

Sepehr Nayebirad, Aida Mohamadi, Hannaneh Yousefi-Koma, Minoo Javadi, Kimia Farahmand, Reza Atef-Yekta, Zahra Tamartash, Mana Jameie, Amir Mohammad Mohammadzadegan, Hoda Kavosi

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMJ open respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 13 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 13 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Tripartite motif containing 21 autoimmunity primes CD8Arthritis research & therapy · 2026
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sepehr NayebiradTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Aida MohamadiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6921-0108
Hannaneh Yousefi-KomaSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Minoo JavadiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Kimia FarahmandRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Reza Atef-YektaDepartment of Anesthesiology, Tehran University of Medical Sciences, Tehran, Iran.
Zahra TamartashRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mana JameieTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Amir Mohammad MohammadzadeganRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Hoda KavosiRheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran h-kavosi@sina.tums.ac.ir.
Tehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesInterstitial lung disease (ILD) is an important manifestation of autoimmune diseases that can lead to morbidity and mortality. Although several autoantibodies have been linked with ILD presentation and adverse outcomes, the association of anti-Ro52 antibody with ILD is less studied. Hence, we investigated this association in various autoimmune diseases in the current study.

designWe designed a systematic review and meta-analysis and did a comprehensive search from inception until 2 January 2023. DATA SOURCES: A systematic search was conducted in four electronic databases: PubMed, Web of Science, Scopus and Embase. ELIGIBILITY CRITERIA: Observational studies that reported ILD diagnosis (outcome) and anti-Ro antibody (exposure) status in any autoimmune conditions (population) were included. The association between rapidly progressive ILD (RP-ILD) and anti-Ro52 was studied in idiopathic inflammatory myopathies (IIM). DATA EXTRACTION AND SYNTHESIS: Collected data included study characteristics and ORs with 95% CIs. Quality assessment was performed using a modified version of the Newcastle-Ottawa Scale for cross-sectional studies. Random effects meta-analysis was used to pool the effect estimates.

resultsA total of 2353 studies were identified, from which 59 articles met the eligibility criteria. Anti-Ro52/SSA positivity was associated with ILD in all autoimmune disease subgroups: IIM (OR=3.08; 95% CI: 2.18 to 4.35; p value<0.001; I

conclusionAnti-Ro52/SSA positivity is associated with a higher frequency of ILD diagnosis in various autoimmune diseases. Anti-Ro52/SSA is also linked with a more severe lung involvement (RP-ILD). Future studies can investigate the benefits of screening for anti-Ro52 and its association with ILD development. PROSPERO REGISTRATION NUMBER: CRD42022381447.

Indexed as

Autoimmune DiseasesLung Diseases, InterstitialMyositisScleroderma, SystemicAutoantibodiesCross-Sectional StudiesHumansAutoantibodiesinterstitial fibrosissystemic disease and lungs

Identifiers

PMID38030264
PMCPMC10689422
OpenAlexW4389132875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.